| 1 |
35051313 | circKCNN2 suppresses the recurrence of hepatocellular carcinoma at least partially via regulating miR-520c-3p/methyl-DNA-binding domain protein 2 axis. | 2022 Jan |
3 |
| 2 |
35466502 | Ferroptosis is induced by lenvatinib through fibroblast growth factor receptor-4 inhibition in hepatocellular carcinoma. | 2022 Apr 25 |
8 |
| 3 |
33390501 | Effect of Lenvatinib on a Hepatocellular Carcinoma with Fibroblast Growth Factor Receptor 4 Expression: A Case Report and Review of the Literature. | 2021 Jun 1 |
2 |
| 4 |
33674622 | The impact of FGF19/FGFR4 signaling inhibition in antitumor activity of multi-kinase inhibitors in hepatocellular carcinoma. | 2021 Mar 5 |
1 |
| 5 |
34036623 | Lenvatinib Targets FGF Receptor 4 to Enhance Antitumor Immune Response of Anti-Programmed Cell Death-1 in HCC. | 2021 Nov |
4 |
| 6 |
34884875 | Evaluating the Effect of Lenvatinib on Sorafenib-Resistant Hepatocellular Carcinoma Cells. | 2021 Dec 2 |
2 |
| 7 |
32034430 | Expression of fibroblast growth factor receptor 4 and clinical response to lenvatinib in patients with anaplastic thyroid carcinoma: a pilot study. | 2020 May |
4 |
| 8 |
32677805 | Tumor Fibroblast Growth Factor Receptor 4 Level Predicts the Efficacy of Lenvatinib in Patients With Advanced Hepatocellular Carcinoma. | 2020 May |
1 |
| 9 |
33051476 | Influence of NOS3 rs2070744 genotypes on hepatocellular carcinoma patients treated with lenvatinib. | 2020 Oct 13 |
1 |
| 10 |
29468981 | Lenvatinib in the Therapy of Aggressive Thyroid Cancer: State of the Art and New Perspectives with Patents Recently Applied. | 2018 |
1 |
| 11 |
29517103 | Lenvatinib exhibits antineoplastic activity in anaplastic thyroid cancer in vitro and in vivo. | 2018 May |
1 |
| 12 |
29656442 | Treatment-emergent hypertension and efficacy in the phase 3 Study of (E7080) lenvatinib in differentiated cancer of the thyroid (SELECT). | 2018 Jun 1 |
1 |